New York-based Schrödinger, Inc. (NASDAQ: SDGR), a leading software provider in accelerating drug discovery, has announced a strategic research collaboration and license agreement with Novartis (NYSE: NVS). This partnership is aimed at advancing multiple development candidates into Novartis’s portfolio for further development. Additionally, the two companies have reached an expanded three-year software agreement.
Software Agreement and Technology Deployment
Under the expanded agreement, Novartis will deploy Schrödinger’s full suite of drug discovery technologies across its research sites. This includes improved access to Schrödinger’s computational predictive modeling technology and enterprise informatics platform, enabling Novartis to operate at an industry-leading scale.
Financial Terms of the Agreement
The terms of the agreement include an upfront payment of USD 150 million from Novartis to Schrödinger. Novartis is also committed to paying USD 892 million in research, development, and regulatory milestone payments. Furthermore, Schrödinger is eligible for up to USD 1.38 billion in commercial milestones, along with tiered mid single-digit to low double-digit royalties on net sales of each product commercialized by Novartis.
Collaboration Responsibilities
Schrödinger and Novartis will share responsibility for the discovery of development candidates under the collaboration. Novartis will take the lead on clinical development, manufacturing, and global commercialization of the products.-Fineline Info & Tech
Leave a Reply